PL2917229T3 - Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania - Google Patents

Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania

Info

Publication number
PL2917229T3
PL2917229T3 PL13791794T PL13791794T PL2917229T3 PL 2917229 T3 PL2917229 T3 PL 2917229T3 PL 13791794 T PL13791794 T PL 13791794T PL 13791794 T PL13791794 T PL 13791794T PL 2917229 T3 PL2917229 T3 PL 2917229T3
Authority
PL
Poland
Prior art keywords
hla
antibodies
fragments
alpha
protein
Prior art date
Application number
PL13791794T
Other languages
English (en)
Inventor
Maria de las Nieves Loustau
Julien Caumartin
Pierre Langlade-Demoyen
Original Assignee
Invectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47221996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2917229(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Invectys filed Critical Invectys
Publication of PL2917229T3 publication Critical patent/PL2917229T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL13791794T 2012-11-12 2013-11-12 Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania PL2917229T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306398.4A EP2730588A1 (en) 2012-11-12 2012-11-12 Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
PCT/EP2013/073648 WO2014072534A1 (en) 2012-11-12 2013-11-12 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.
EP13791794.4A EP2917229B1 (en) 2012-11-12 2013-11-12 Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof

Publications (1)

Publication Number Publication Date
PL2917229T3 true PL2917229T3 (pl) 2021-01-11

Family

ID=47221996

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13791794T PL2917229T3 (pl) 2012-11-12 2013-11-12 Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania

Country Status (7)

Country Link
US (1) US10005845B2 (pl)
EP (2) EP2730588A1 (pl)
CA (1) CA2891184A1 (pl)
DK (1) DK2917229T3 (pl)
ES (1) ES2786049T3 (pl)
PL (1) PL2917229T3 (pl)
WO (1) WO2014072534A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US20190119385A1 (en) * 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
CA3025681A1 (en) * 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
AU2017301705A1 (en) * 2016-07-26 2019-01-24 North Carolina State University Vector-mediated immune tolerance in the eye
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CA3063959A1 (en) * 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
EP3434688A1 (en) * 2017-07-24 2019-01-30 Commissariat à l'Energie Atomique et aux Energies Alternatives Hla-g transcripts and isoforms and their uses
US20210115137A1 (en) * 2018-03-13 2021-04-22 National University Corporation Hokkaido University Prophylactic or therapeutic agent for tumors, pd-l1 inhibitor, screening method for prophylactic or therapeutic agent for tumors, and screening method for pd-l1 inhibitor
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
US11492387B2 (en) * 2018-05-09 2022-11-08 Tianjin Dongya Biological Technology Co., Ltd. Broad spectrum vaccine, preparing method and application thereof
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
WO2020023268A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
BR112021005868A2 (pt) 2018-09-27 2021-10-19 Tizona Therapeutics Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
US12012454B2 (en) * 2021-03-24 2024-06-18 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
AU2023216270A1 (en) 2022-02-04 2024-08-15 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
CN115894687B (zh) * 2022-03-31 2024-06-07 台州恩泽医疗中心(集团) 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途
CN119569893B (zh) * 2023-09-06 2025-10-31 上海恩凯细胞技术有限公司 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用
CN121005780A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 靶向hla-g的抗体或其抗原结合片段及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790638B1 (en) * 1998-02-20 2004-09-14 Commissariat A L'energie Atomique Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
WO2002022784A2 (en) 2000-09-15 2002-03-21 University Of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
WO2005042693A2 (ja) 2003-11-04 2005-05-12 The Animal Engineering Research Institute Ｈｌａ−ｅキメラ分子
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
WO2009100135A2 (en) * 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
EP2427203B1 (en) * 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
CA3025681A1 (en) 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies

Also Published As

Publication number Publication date
US10005845B2 (en) 2018-06-26
EP2917229B1 (en) 2020-01-08
US20160272724A1 (en) 2016-09-22
CA2891184A1 (en) 2014-05-15
EP2730588A1 (en) 2014-05-14
ES2786049T3 (es) 2020-10-08
DK2917229T3 (da) 2020-04-06
EP2917229A1 (en) 2015-09-16
WO2014072534A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
ZA201407927B (en) Anti-egfr antibodies and uses thereof
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201406967B (en) Anti sez6 antibodies and methods of use
ZA201500887B (en) Human anti-cd27 antibodies, methods and uses
LT3912642T (lt) Modifikuotas antikūnas, antikūno konjugatas ir jų gamybos būdas
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
IL233757A0 (en) Anti '1m e-gi antibodies and methods of using them
IL237522A0 (en) Bioconjugates involving adapted antigens and their uses
SG11201502757QA (en) Anti-c16orf54 antibodies and methods of use thereof
HUE037613T2 (hu) Anti-TLR4 antitestek és azok felhasználása
IL238223B (en) Nanoparticle mhc antigen complex, method for preparation and composition containing it
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
ZA201407309B (en) Antigens and antigen combinations
IL234492A (en) Crystalline forms of 5α - androstane - 3 β, 56β, - triol and methods for their preparation
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
GB201207383D0 (en) Antigens and antigen combinations
GB201207385D0 (en) Antigens and antigen combinations